Drug Profile


Alternative Names: CCX-282; CCX-282B; GSK'786; GSK-1605786; GSK-1605786-A; Traficet-EN

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; GlaxoSmithKline
  • Class Anti-inflammatories; Small molecules; Sulfonamides
  • Mechanism of Action CCR9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Crohn's disease; Ulcerative colitis
  • No development reported Coeliac disease

Most Recent Events

  • 20 Oct 2014 Efficacy and adverse events data from the phase III SHIELD-4 trial in Crohn's disease presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology (ACG-2014)
  • 19 May 2014 Vercirnon is available for licensing as of 19 May 2014.
  • 25 Sep 2013 GlaxoSmithKline terminates the global phase III SHIELD programme for Crohn's disease (NCT01316939, NCT01318993 and NCT01536418)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top